Pharma News
This Week
Dec 12, 2025
Hangzhou Zhongmei Huadong Pharmaceutical secures patents for innovative antibody-drug conjugates.
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has patented new antibody-drug conjugates that combine antibodies with a cytotoxic drug via a linker, aimed at enhancing cancer treatment efficacy.
Dec 12, 2025
Lilly's new drug outperforms Zepbound in weight loss during final trial phase | WTVB
Eli Lilly's next-generation obesity drug, retatrutide, demonstrated an average weight loss of 28.7% in a late-stage trial, outperforming its existing drug Zepbound. The once-weekly injection, which activates GLP-1, GIP, and glucagon receptors, shows promise in the obesity market. Shares rose 1.4% following the announcement, while rival Novo Nordisk's stock briefly dipped.
Dec 12, 2025
Teva complies with FTC regarding Orange Book entries - BioWorld
The U.S. FTC applauded Teva Pharmaceutical Industries Ltd. for requesting the FDA to eliminate over 200 patent listings from the Orange Book, marking a significant move in the pharmaceutical industry.
Dec 11, 2025
2025: A Recap of the Bio/Pharma Sector - Insights from the DCAT Value Chain
In 2025, the bio/pharmaceutical industry faced significant challenges due to evolving US tariff policies impacting active pharmaceutical ingredients (APIs) and contract development and manufacturing organizations (CDMOs). Notably, Novo Nordisk's $11 billion acquisition of Catalent bolstered its production capabilities for glucagon-1 peptide (GLP-1) agonists. The year also saw promising new drug approvals and growth in antibody drug conjugates (ADCs) in oncology.
Dec 11, 2025
Biopharmaceutical Investments Yield Superior Returns as Valuations Rebound
Biopharma and life sciences hedge funds experienced significant gains in November, with several funds surging by double digits. RTW Investments rose 12.96% and is up 75.94% for the year, driven by Madrigal Pharmaceuticals. Terns Pharmaceuticals tripled in value after positive trial results. Morgan Stanley predicts continued growth in the sector, fueled by interest rate cuts and M&A activity.
Dec 11, 2025
3SBio prepares for pharmaceutical competition with a $400 million equity initiative - Bamboo Works
3SBio Inc. is raising HK$3.12 billion ($400 million) through a share placement to fund R&D for next-generation cancer drugs, following a significant licensing deal with Pfizer. The company is also divesting its hair-loss subsidiary, Mandi International, to focus on innovative pharmaceuticals. Despite recent stock fluctuations, 3SBio's shares have surged over 400% this year, reflecting strong market confidence.
Dec 11, 2025
EU to incentivize antibiotic development through updated pharmaceutical regulations - Medical Xpress
The EU has approved a reform of pharmaceutical rules to enhance innovation and combat antimicrobial resistance, benefiting antibiotic developers with extended market protections. The new "pharma package" allows up to 11 years of coverage for priority antibiotics and introduces a transferable voucher for additional market protection. The changes aim to address the rising threat of drug-resistant infections.
Dec 11, 2025
Implications of IRA Drug Pricing for PBMs, Health Plans, and Patients
As Medicare Part D drug price negotiations begin in January 2026, experts warn of complexities affecting savings. Initial discounts for drugs like Eliquis (apixaban) may not yield expected benefits, with increased utilization management likely. Future negotiations could impact drugs like Keytruda (pembrolizumab) and Opdivo (nivolumab), which may be exempt from price negotiations for years.
Dec 11, 2025
Cloudbreak Pharma Rises Over 80% Due to Several Factors, Leading to a Reassessment of Its Value
Cloudbreak Pharma (2592.HK) has seen its stock surge over 80% following positive developments, including securing patents for its myopia treatment CBT-009 and advancing another drug, CBT-004, towards Phase 3 trials. The company appointed Michael Rowe as Chief Business Officer to enhance commercialization efforts. With a strong pipeline and favorable market conditions, Cloudbreak is positioned for significant growth.
Dec 11, 2025
An All-Inclusive Guide to Generic Medications - openPR.com
The Global Generic Drugs market is poised for growth due to government policies, regulatory support, and patent expirations. Key players include Teva Pharmaceutical Industries Ltd, Viatris Inc, and Dr. Reddy's Laboratories Ltd. The expiration of branded drug patents allows generic manufacturers to offer bioequivalent versions at lower prices, creating significant market opportunities.
Dec 11, 2025
As major pharmaceutical companies encounter a 'patent cliff', China's biotechnology surge is rising as a key player in the sector...
Concerns are growing over rising regulatory risks in the US for Big Pharma, despite a one-year trade truce. The article highlights China's dominance in producing essential drug ingredients, emphasizing the need for the US to decouple in areas of national security, particularly regarding supply chains for antibiotics, while acknowledging the potential for Chinese innovation in novel therapies.
Dec 11, 2025
Savara prepares to secure EPO patent for MOLBREEVI liquid, ensuring protection until 2041 | SVRA Stock Update
Savara Inc. announced that the European Patent Office intends to grant a patent for the liquid formulation of MOLBREEVI, a therapy for autoimmune pulmonary alveolar proteinosis (PAP). This patent will protect MOLBREEVI in Europe until March 2041. The company is also preparing to resubmit its Biologics License Application to the FDA and submit Marketing Authorization Applications in the EU and U.K. by early 2026.
Dec 11, 2025
Pune FDA Discovers a Multi-State Counterfeit Chymoral Forte Operation Linked to Bihar
The Maharashtra FDA has uncovered a multi-state counterfeit operation distributing fake Chymoral Forte tablets, an anti-inflammatory drug containing Trypsin-Ch. The investigation traced the counterfeit network back to Bihar, highlighting ongoing concerns about drug safety and regulation in India.
Dec 11, 2025
Pharmalittle: New obesity medication from Lilly and European pharmaceutical regulations - STAT News
Eli Lilly's obesity drug, retatrutide, demonstrated significant weight loss in a Phase 3 trial, with participants losing up to 28.7% of their weight. However, high discontinuation rates due to side effects were noted. Meanwhile, EU negotiators have agreed on a "pharma package" to modernize medicine rules, enhancing data protection and market access for new drugs.
Dec 11, 2025
Two experts in drug development from Johns Hopkins have been appointed to the National Academy of Inventors.
Two scientists from Johns Hopkins School of Medicine, Jun Liu and Barbara Slusher, have been named fellows of the National Academy of Inventors for their contributions to drug development. Liu is recognized for his rapafucin platform and drug repurposing efforts, while Slusher leads a major drug discovery program and has over 100 patents. They will be honored at the NAI conference in June 2025.
Dec 11, 2025
AI in Pharmaceutical Research Challenges Patent Regulations | Goodwin - JDSupra
Artificial intelligence (AI) is revolutionizing drug discovery, projected to generate $13.4 billion by 2035. However, legal uncertainties regarding AI inventorship pose challenges for patenting innovations. Companies must document human contributions to AI-generated compounds to secure patents. The evolving landscape of AI in pharmaceuticals could reshape research strategies and economic incentives, with significant implications for future drug development.
Dec 11, 2025
Lilly's triple-action medication raises awareness in the obesity sector | BioPharma Dive
Eli Lilly's experimental obesity drug, retatrutide, demonstrated significant weight loss in a Phase 3 study, with patients losing an average of 28.7% of their body weight over 68 weeks. The trial also showed relief from knee osteoarthritis pain. Despite side effects, the results position Lilly to lead in the competitive obesity treatment market, surpassing its own Zepbound and Novo Nordisk's Ozempic.
Dec 11, 2025
Lilly's New Drug Demonstrates Superior Weight Loss Results Compared to Zepbound in Final Phase Trial
Eli Lilly's next-generation obesity drug, retatrutide, demonstrated an average weight loss of 28.7% in a late-stage trial, outperforming its existing drug Zepbound. The once-weekly injection also alleviated knee pain in participants. Despite some side effects, including dysesthesia, the drug is expected to be a significant addition to Lilly's portfolio, with trials for obesity and type 2 diabetes ongoing until 2026.
Dec 10, 2025
Novo Nordisk files lawsuit against Sun Pharma regarding diabetes medication patent - NewsBytes
Novo Nordisk accuses Sun Pharma of infringing its Indian patents for semaglutide formulations and delivery devices, valid until March 2026. The outcome could influence when companies like Cipla and Mankind can release their versions. Sun Pharma is poised to enter the GLP-1 market, making the legal proceedings critical to the industry's future.
Dec 10, 2025
Guaranteeing Availability of Essential Medications: Advocating for Mandatory Licensing in Rare Disease Treatment
India faces significant challenges in providing affordable treatments for rare diseases like spinal muscular atrophy (SMA) and haemophilia. The country's compulsory licensing framework, established under the Patents Act of 1970, allows for the production of generic drugs to improve access. However, limited use of this provision has hindered progress, prompting calls for stronger government action to ensure equitable healthcare.
Dec 10, 2025
Sun Pharma announces it will refrain from marketing semaglutide medications in India until the patent held by Novo Nordisk lapses.
The Delhi High Court is mediating a patent dispute between Novo Nordisk and Sun Pharma over semaglutide, the active ingredient in Novo Nordisk's Ozempic. Sun Pharma has agreed not to sell semaglutide-based drugs in India until March 2026, while continuing exports. The case highlights a competitive landscape, with other companies like Mankind Pharma and Cipla eyeing market entry post-patent expiration.
Dec 10, 2025
Authorities Conduct Raid at Jan Aushadhi Kendra in Lucknow's RML Hospital - Drugs Control Media Services
A surprise inspection by the Uttar Pradesh Drug Control Department revealed that the Jan Aushadhi Kendra at Ram Manohar Lohia (RML) Hospital in Lucknow was selling branded, expensive medicines instead of the intended cheap generic drugs. This discovery raises concerns about compliance with government health initiatives aimed at providing affordable medication.
Dec 10, 2025
Novo files lawsuit to prevent Sun Pharma and Alkem from producing and selling Semaglutide.
Novo Nordisk has filed a petition in the Delhi High Court to prevent Sun Pharma and Alkem Laboratories from manufacturing or selling semaglutide, the active ingredient in its popular drug Wegovy, citing patent infringement concerns.
Dec 10, 2025
Teva Eliminates More than 200 Incorrect Patent Registrations Following FTC Pressure
Teva Pharmaceuticals has requested the FDA to remove over 200 improper patent listings from its Orange Book following a challenge from the Federal Trade Commission (FTC). This move aims to enhance competition and lower drug prices for more than 30 drugs, including those for asthma, diabetes, and COPD. The FTC continues to monitor the industry for anticompetitive practices.
Dec 10, 2025
Million-yuan "Cancer-fighting Injections" and Extended-release Cholesterol-lowering Injections Experience ... - 36氪
The National Healthcare Security Administration has added 114 new drugs to China's medical insurance catalog, including Tirzepatide, Inclisiran, and Dotinorle tablets. A new commercial insurance catalog features 19 products, including CAR-T therapies, with price reductions of 15%-50%. This initiative aims to improve access to high-priced innovative drugs and enhance the collaboration between basic and commercial insurance systems.
Dec 10, 2025
Comparing JNJ and PFE: Which Leading Pharmaceutical Stock is the Superior Investment Choice Today? - TradingView
Johnson & Johnson (JNJ) and Pfizer (PFE) are competing healthcare giants with diverse portfolios. JNJ shows strong growth in its Innovative Medicine and MedTech segments, driven by key drugs like Darzalex and new launches. In contrast, Pfizer's oncology sales are robust, but it faces challenges from declining COVID product sales and upcoming patent expirations. JNJ is viewed as a better investment due to its growth prospects and consistent dividend increases.
Dec 10, 2025
Delhi High Court permits Sun Pharma to produce and export its proprietary weight loss medication.
The Delhi High Court has permitted Sun Pharma to manufacture and export its version of semaglutide, the diabetes and anti-obesity drug from Novo Nordisk, known as Wegovy. However, Sun is prohibited from selling the drug in India until March 2026, when Novo Nordisk's secondary patent expires. The case will be reviewed again on February 19.
Dec 10, 2025
Following Dr. Reddy's approval, Sun Pharma receives permission from the Delhi High Court to produce and export semaglutide.
The Delhi High Court has permitted Sun Pharma to manufacture and export its version of semaglutide, the active ingredient in Novo Nordisk’s diabetes and weight-loss drugs, Ozempic and Wegovy. This follows a similar ruling for Dr Reddy’s Lab, amid ongoing patent disputes. Sun Pharma cannot sell the drug in India until the patent expires in March 2026.
Dec 10, 2025
Sanofi Under Investigation for Promising Multiple Sclerosis Drug Ahead of Key EMA Conference
Sanofi is set to defend its multiple sclerosis (MS) drug at an oral explanation meeting with the European Medicines Agency (EMA) this week.
Dec 10, 2025
Otsuka's Pharmaceutical Patent Term Extension Comes to an End - Lexology
The Full Federal Court of Australia ruled in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd that patent claims for formulations of active pharmaceutical ingredients (APIs) do not qualify as "pharmaceutical substances" under the Patents Act, impacting patent term extensions (PTE). This decision affects Otsuka's aripiprazole formulation patent and future PTE applications for similar formulations.
Dec 10, 2025
Computational Models of Cardiomyocytes Improve Drug Safety Evaluations Through Simulation...
Advancements in cardiology are leveraging computational cardiomyocyte models to enhance drug safety assessments. These models simulate heart muscle cell behavior, improving predictions of drug interactions and potential cardiac side effects. This innovative approach aims to reduce reliance on traditional animal testing, leading to more accurate evaluations and safer drug development processes.
Dec 10, 2025
Teva eliminates more than 200 incorrect patent entries following pressure from the US Federal Trade Commission | MLex
Teva Pharmaceuticals has requested the US FDA to remove over 200 improper patent listings from the Orange Book, following a challenge from the Federal Trade Commission. This move aims to enhance competition and reduce drug prices, as the FTC had previously issued warning letters to Teva and other companies regarding disputed listings.
Dec 10, 2025
Exploring AI in Pharmaceutical Development and Intellectual Property Regulations - Goodwin
Artificial intelligence (AI) is revolutionizing drug discovery, projected to generate $13.4 billion by 2035. However, legal uncertainties around patent inventorship complicate the process, as courts have yet to define human contribution in AI-generated inventions. Companies must document workflows to establish human involvement, balancing disclosure without revealing proprietary methods, as the first patent litigations on AI drugs loom in the coming years.
Dec 10, 2025
Hims experiences a decline following the introduction of a bill by US legislators aimed at regulating compounding practices.
Hims & Hers shares fell after Congress introduced the SAFE Drugs Act of 2025, which could limit the company's ability to sell compounded versions of weight-loss drugs from Eli Lilly and Novo Nordisk. Analysts warn the bill may significantly impact Hims' revenue growth from GLP-1s, as it raises standards for dispensing compounded medications.
Dec 9, 2025
FDA's Initiative to Lower Drug Prices Through Biosimilar Strategy Relies on Additional Reforms - Bloomberg Law News
The FDA aims to reduce drug costs by expediting approvals for biosimilars, similar to AbbVie’s Humira and Merck’s Keytruda. Despite 79 biosimilars approved since 2015, market access remains limited due to patent issues and pharmacy benefit managers' influence. Experts stress that additional policy reforms are necessary to enhance biosimilar adoption and affordability.
Dec 9, 2025
AP Drugs Control Department Set to Establish 27 New Office Buildings, Reports DrugsControl Media Services
The Andhra Pradesh drugs control department is expanding its infrastructure by constructing 27 new office buildings, supported by financial assistance from a centrally sponsored scheme by the Union health ministry and the state government.
Dec 9, 2025
Novo seeks legal action to prevent Sun Pharma and Alkem from producing and selling weight loss medication.
Novo Nordisk has filed a lawsuit in the Delhi High Court to prevent Sun Pharma and Alkem Laboratories from producing semaglutide, the active ingredient in its drug Wegovy, amid ongoing patent infringement disputes. This legal action follows a court ruling allowing Dr. Reddy’s Laboratories to manufacture semaglutide for export, intensifying competition in the growing GLP-1 market for diabetes and obesity treatments.
Dec 9, 2025
Terns' leukemia medication may outperform Novartis' top-selling drug - STAT News
Terns Pharmaceuticals announced promising early efficacy data for its next-generation CML drug, TERN-701, at the American Society for Hematology. The drug achieved a 64% major molecular response rate at 24 weeks in heavily pre-treated patients, surpassing Novartis’ Scemblix. Safety profiles were manageable, with no significant toxicities reported.
Dec 9, 2025
Zydus to launch in the US biosimilar sector through collaboration with Germany's Formycon on Keytruda.
Zydus Lifesciences has signed an exclusive licensing and supply agreement with Formycon AG to commercialize FYB206, a biosimilar of Merck's Keytruda, in the US and Canada. This partnership aims to provide a cost-effective alternative in the oncology market as Keytruda's patents expire in 2028, potentially opening a multi-billion-dollar opportunity for biosimilars.
Dec 9, 2025
Zacks Industry Analysis Focuses on Sandoz, Teva Pharmaceuticals, and Dr. Reddy's
Sandoz, Teva Pharmaceuticals, and Dr. Reddy’s Laboratories are highlighted as key players in the generic drug market, which faces challenges like price erosion and competition. Sandoz has seen growth in its biosimilars, while Teva focuses on complex generics. Dr. Reddy's is expanding its portfolio with 75 FDA filings pending. The industry shows promising prospects amid evolving market dynamics.
Dec 9, 2025
Medical professionals indicate that weight-loss medications address a treatment void for women suffering from the hormonal condition PCOS.
Women with polycystic ovary syndrome (PCOS) are increasingly using weight-loss drugs like Eli Lilly's Zepbound and Novo Nordisk's Wegovy to manage symptoms, with prescriptions rising over sevenfold since 2021. Despite improvements, experts highlight a lack of clinical trials for PCOS, viewing it as a missed opportunity in women's health. More research is needed to understand the relationship between GLP-1 drugs and PCOS.
Dec 9, 2025
Novo Nordisk seeks to prevent Sun Pharma from selling semaglutide, returns to Delhi High Court.
Novo Nordisk has filed a lawsuit in the Delhi High Court to prevent Sun Pharmaceutical from dealing with semaglutide, the active ingredient in its drug Ozempic. This follows a recent ruling allowing Dr. Reddy’s Laboratories to manufacture the drug while challenging Novo Nordisk's patent. The court is set to hear the case against Sun Pharma soon.
Dec 9, 2025
Solicitor General calls on the Supreme Court to reconsider 'skinny labeling' and the availability of generic medications.
The U.S. solicitor general has urged the Supreme Court to review a case regarding skinny labels for generic drugs, which could impact the availability of lower-cost options. Skinny labeling allows generics to market for specific uses while avoiding patent infringement lawsuits, a practice established under the Hatch-Waxman Act to enhance market competition.
Dec 9, 2025
China Takes Center Stage as Big Pharma Faces Patent Expiration: Juliana Liu - Bloomberg Law News
China's biotech companies are emerging as a solution for pharmaceutical firms facing the impending "patent cliff" as patents on top-selling drugs expire. With the potential for new blockbuster drugs generating billions annually, the industry is under pressure to innovate and adapt to the competition from generics and biosimilars.
Dec 9, 2025
Semaglutide Patent Dispute: Following Dr. Reddy's Setback, Novo Nordisk Takes Legal Action Against Sun Pharma in Delhi High Court
Novo Nordisk has filed a lawsuit against Sun Pharmaceutical in the Delhi High Court, seeking to prevent the company from dealing with semaglutide, the active ingredient in its drug Ozempic. This follows a recent setback against Dr. Reddy’s Laboratories, which was allowed to manufacture semaglutide but barred from selling it in India until the patent expires.
Dec 9, 2025
Upcoming expirations of GLP-1 drug patents attract generic manufacturers - C&EN
Novo Nordisk's patent on semaglutide, the active ingredient in its diabetes drug Ozempic and weight-loss drug Wegovy, will expire in 2026 in several countries, including India and China. This opens the market for generic-drug makers, potentially reducing prices by up to 80% and increasing accessibility for patients with diabetes and obesity. Companies like Lupin and Dr. Reddy’s Laboratories are preparing to launch generic versions.
Dec 9, 2025
FDA Guidance on Biosimilars Emphasizes Glycosylation Analysis and Enhances Strategic Approaches
The FDA's September 2025 guidance emphasizes the importance of detailed glycosylation characterization in evaluating protein biosimilars, particularly antibodies. This focus on posttranslational modifications affects clinical function and patent strategies, allowing for extended protection of antibodies with specific glycosylation profiles. The guidance encourages sponsors to use scientifically sound methods for glycan profiling to ensure biosimilarity and regulatory compliance.
Dec 9, 2025
IPC set to release the 10th edition of the IP to enhance drug standards in India.
The Indian Pharmacopoeia Commission (IPC) is set to release the 10th edition of the Indian Pharmacopoeia (IP 2026) on January 2, 2026, aimed at enhancing drug standards in India.
Dec 9, 2025
Cline presents a bipartisan proposal aimed at safeguarding skinny labels and reducing medication expenses - Rocktown Now
Virginia Representative Ben Cline and California Representative Zoe Lofgren have introduced the Skinny Labels, Big Savings Act, aimed at reducing prescription drug costs by protecting generic drugmakers from patent-related lawsuits. The bill seeks to enhance federal protections for "skinny labels," expediting affordable medication access while maintaining valid patent protections. Advocacy groups support the measure, highlighting its potential to lower costs for patients.
Dec 9, 2025
Russia secures patent for its fourth vaccine targeting the SAT-2 serotype of foot-and-mouth disease - GxP News
The All-Russian Research Institute of Animal Health has patented a new vaccine against foot-and-mouth disease serotype SAT-2, enhancing Russia's biological security. The inactivated emulsion vaccine, SAT-2/VII/Ghb-12, has proven safe and effective in trials, ensuring a strong immune response in farm animals. This development is crucial as outbreaks of SAT-2 continue globally.
Dec 9, 2025
CDSCO introduces a new online module for the risk classification of medical devices.
The Central Drugs Standard Control Organisation (CDSCO) has introduced a new online risk classification module for medical devices, aimed at streamlining regulatory approval processes. This initiative is expected to enhance efficiency in the approval of medical devices, excluding in-vitro diagnostics, in India.
Dec 8, 2025
Patentability of Biopharmaceuticals in India Under Scrutiny in Amgen Case - Mondaq
The Madras High Court ruled on Amgen's patent application for a lyophilized peptibody formulation, addressing issues of non-obviousness and sufficiency of disclosure. The court found that the specific combination of excipients and their concentrations were not obvious from prior art, allowing Amgen to proceed with its patent despite challenges regarding synergy and disclosure for only one variant.
Dec 8, 2025
Dr. Reddy's Receives Approval for Exporting Weight Loss Medication | - Chemical Industry Digest
Dr Reddy’s Laboratories Ltd has received permission from the Delhi High Court to manufacture and export its diabetes and anti-obesity drug semaglutide, used in Novo Nordisk's Ozempic, Wegovy, and Rybelsus. While domestic sales remain restricted due to a patent dispute, the ruling allows the company to build export inventory and maintain supply chains for international markets.
Dec 8, 2025
Halozyme secures German court order halting the distribution of Merck's Keytruda.
Halozyme Therapeutics achieved a legal victory in Germany, as a court ordered Merck to cease distribution of Keytruda SC due to patent infringement. The Munich Regional Court granted a preliminary injunction against Merck's launch activities, while patients can still access the IV formulation. Halozyme is also pursuing legal action against Merck in the US regarding Keytruda SC's patent violations.
Dec 8, 2025
The Significance of the Delhi HC's Semaglutide Decision on Patent Evergreening for Your UPSC Preparation
Novo Nordisk's patent infringement suit against Dr. Reddy’s Laboratories (DRL) over semaglutide was dismissed by the Delhi High Court, citing potential 'evergreening'. The court found no novelty in Novo's second patent for the GLP-1 drug, allowing DRL to manufacture and export its version. Evergreening, which extends drug monopolies, is prohibited under India's Patent Act.
Dec 8, 2025
Not supplying a sample and report to the defendant nullifies the trial according to the Drugs Act.
The Jammu & Kashmir and Ladakh High Court has quashed criminal proceedings under the Drugs and Cosmetics Act, citing the failure to provide a sample and report to the accused as a violation of mandatory safeguards. This decision underscores the importance of due process in drug-related legal cases.
Dec 8, 2025
Renaissance BioScience secures a patent in Mexico for its innovative RNA production and delivery technology.
Renaissance BioScience Corp. has received a new patent from the Mexican patent office for its yeast-based RNA technology, enhancing its IP portfolio. This technology supports the production of RNAi-based biopesticides, offering targeted pest control with environmental safety. Dr. John Husnik emphasized its potential across various multi-billion-dollar markets. The company is based in Vancouver, Canada.
Dec 8, 2025
Exploring the Patent Linkage System for Pharmaceuticals in China: Judicial Developments and Important Insights...
A recent article analyzes China's pharmaceutical patent linkage system, focusing on judicial rules and practical issues. It highlights that not all drug-related patents, particularly crystalline form patents, are registrable. The Supreme People's Court emphasizes a restrictive approach to patent eligibility, aiming to balance original drug protection with generic market entry. Ongoing discussions seek to clarify unresolved practical challenges in patent disputes.
Dec 8, 2025
Halozyme and Quinn Emanuel win preliminary injunction against MSD regarding Keytruda SC - JUVE Patent
MSD's Keytruda, the best-selling drug globally in 2024, faces a legal setback as a Munich court prohibits the launch of its subcutaneous variant, Keytruda SC, due to a patent infringement lawsuit filed by Halozyme Therapeutics. The court's decision, based on Halozyme's MDAS patent claims, does not affect the current infusion administration of Keytruda.
Dec 8, 2025
Can Johnson & Johnson Compensate for Stelara's Loss of Exclusivity, Challenges in MedTech in China, and Legal Issues by 2026?
Johnson & Johnson (JNJ) is grappling with significant challenges, including the loss of patent exclusivity for its key drug Stelara, which has seen a 40% sales decline due to biosimilar competition from companies like Amgen and Teva. Additionally, the Medicare Part D redesign is expected to impact J&J's sales by $2 billion. The company also faces over 73,000 lawsuits related to its talc products.
Dec 8, 2025
In Order to Compete with China in Pharmaceutical Innovation, Major Pharmaceutical Companies and Generic Manufacturers Require the Supreme Court to...
The U.S. biopharma sector faces challenges due to unpredictable patent rulings, particularly in the case of MSN Pharmaceuticals v. Novartis regarding the heart-failure drug Entresto. The Supreme Court's intervention is sought to clarify patent laws and address the "after-arising technology" exception, which hampers innovation and allows outdated patents to block new inventions.
Dec 8, 2025
Overweight and Unmanageable: The Impact of Pharmaceuticalization on Health Rights
Novo Nordisk's unexpected discontinuation of Levemir, its insulin detemir for type 2 diabetes, has led to insulin shortages, highlighting tensions between financial practices and innovation in the pharmaceutical industry. The FDA's regulations on product discontinuation are insufficient to prevent these shortages. Additionally, private equity firms are increasingly investing in obesity treatments, further complicating the landscape of diabetes care.
Dec 8, 2025
Prescription medication costs surge at leading health insurers due to GLP-1 medications - STAT News
Health insurance companies are facing rising medical expenses, particularly due to prescription drugs, especially GLP-1s, which are linked to significant weight loss. Insurers reported drug spending in the first nine months of 2025 exceeding their total for 2024, with increases over 20%. This surge has prompted discussions about potentially discontinuing coverage for these medications.
Dec 8, 2025
Could GLP-1 receptor agonists be the next breakthrough in addiction treatment? - Nature
Researchers are exploring the potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro/Zepbound), in treating addiction, particularly alcohol use disorder. Initial studies show promise, with semaglutide reducing cravings and drinking frequency. However, further trials are needed to understand the mechanisms and ensure safe use, as off-label demand rises amid safety concerns.
Dec 8, 2025
Biogen and Stoke Enhance the Promising Market Potential of Their Epilepsy Medication with Initial Findings on Seizure Reduction
Stoke Therapeutics and Biogen's investigational drug zorevunersen shows promising long-term results in reducing seizure burden in Dravet syndrome patients, with an 82% drop in major motor seizures reported. Analysts at Jefferies estimate zorevunersen could become a blockbuster, predicting increased regulatory activity in 2024. The drug targets SCN1A mutations, addressing the underlying cause of this rare epilepsy.
Dec 8, 2025
Kymera's eczema treatment shows promise in initial trial, potentially competing with Dupixent - STAT News
Kymera Therapeutics announced positive results from its Phase 1 BroADen trial of KT-621, an experimental drug for moderate-to-severe eczema, showing a 63% reduction in disease severity. This positions KT-621 as a competitor to Sanofi and Regeneron's Dupixent, which generated over $14 billion in revenue last year. Kymera's market value is approximately $4.8 billion.
Dec 8, 2025
Terns' medication demonstrates promise in competing with Novartis' leading leukemia therapy.
Terns Pharmaceuticals' experimental drug TERN-701 shows promise in treating chronic myeloid leukemia (CML), outperforming Novartis' Scemblix in reducing diseased white blood cells. In a study, 74% of patients achieved a major molecular response with TERN-701, compared to 25% with Scemblix. The drug also demonstrated a favorable safety profile, raising expectations for its potential market impact.
Dec 8, 2025
Wave Life Sciences Shares Surge 120% Following Significant Fat Loss Results from Obesity Treatment
Wave Life Sciences' stock surged over 120% following positive interim results from its Phase 1 INLIGHT trial for WVE-007, an investigational treatment for obesity. The trial showed significant fat loss and lean mass gains, with a 9.4% drop in visceral fat and good tolerability. Analysts remain optimistic, with ratings reflecting confidence in WVE-007's potential.
Dec 8, 2025
Bulk drug and intermediate imports drop by over 11% in October, according to DrugsControl Media Services.
India's imports of bulk drugs and intermediates fell by 11.14% in October 2025, despite a 20.74% increase in quantity compared to the same month last year. This decline highlights ongoing shifts in the pharmaceutical supply chain and market dynamics.
Dec 8, 2025
Findings from a study on Terns' leukemia medication indicate it may become a successor to Novartis' top-selling drug.
Terns Pharmaceuticals announced promising early results for its leukemia drug, TERN-701, which achieved a 64% major molecular response in advanced-stage chronic myeloid leukemia patients after 24 weeks. This update is expected to attract further investor interest, positioning TERN-701 as a potential successor to a blockbuster drug from Novartis.
Dec 7, 2025
Is it a good time to invest in Vertex Pharmaceuticals after a 10% decline?
Vertex Pharmaceuticals, a leader in cystic fibrosis treatment, has expanded into blood disorders and pain management, generating over $3 billion in revenue last quarter. Its CFTR modulators treat 95% of CF patients, while new drugs Casgevy and Journavx show promising growth potential. Despite risks in clinical trials, Vertex remains a strong investment opportunity.
Dec 7, 2025
Countrywide Operation Targets Narcotics Trade: Significant Seizures of Codeine Syrup
Indian authorities have launched a nationwide crackdown on the illegal narcotic drug trade, resulting in significant seizures of codeine syrup, Pregabalin capsules, and Tapentadol tablets. The operation has led to multiple arrests and intensified financial investigations into the illicit activities surrounding these controlled substances.
Dec 7, 2025
Bengaluru is set to establish a central laboratory for drug testing, aimed at reducing the turnaround time for sample analysis results.
Bengaluru is set to establish a Central Drug Testing Laboratory to expedite the analysis of drug samples, aiming to identify adulterated or substandard drugs more efficiently. Currently, similar facilities exist in Kolkata, Hyderabad, Chennai, Mumbai, and Kasauli. This initiative is expected to significantly reduce wait times for sample analysis reports in Karnataka.
